The horizon may be out of sight, but thanks to the HORIZON trial, a brighter future for glaucoma patients is now in sight. Combined glaucoma and cataract surgery has become increasingly common in North America with the introduction of minimally invasive glaucoma surgery devices and techniques. The HORIZON trial compared clinical outcomes of patients following cataract surgery with (n=369) and without a Hydrus Microstent (n=187)
Key Points:
- At 5 years, the Hydrus Microstent and Cataract Surgery group (HMS) included a higher proportion of eyes with IOP of 18 mmHg or less without medications than the Cataract Surgery Only (CS) group (49.5% vs. 33.8%; P = 0.003)
- The HMS group had a greater likelihood of IOP reduction of 20% or more without medications than the CS group (54.2% vs. 32.8%; P < 0.001)
- The number of glaucoma medications was 0.5 ± 0.9 in the HMS group and 0.9 ± 0.9 in the CS group (P < 0.001), and 66% of eyes in the HMS group were medication free compared with 46% in the CS group (P < 0.001)
- No clinical or statistically significant differences were found in the rate of endothelial cell loss from 3 to 60 months between the HMS and CS alone groups (P = 0.261)
Overall, the HORIZON landmark study demonstrated that use of a Schlemm's canal microstent in addition to traditional cataract surgery was found to be safe and resulted in lowered intraocular pressure and a reduction in medication use. The study also found that the long-term presence of the microstent did not have a negative impact on the corneal endothelium.
|
|